Cymbalta Labeling Hints At Side Effect Claim; Lilly Will Test In Phase IV
Executive Summary
Lilly's post-marketing research plans for the antidepressant Cymbalta may help the company establish a claim concerning the drug's effect on female sexual dysfunction
You may also be interested in...
Lunesta, Crestor, Sanctura Among New Products In UnitedHealth Registry
Sepracor's insomnia agent Lunesta, AstraZeneca's statin Crestor and Indevus' overactive bladder therapy Sanctura are among the new products to be included in UnitedHealth's postmarketing surveillance drug registry
Lunesta, Crestor, Sanctura Among New Products In UnitedHealth Registry
Sepracor's insomnia agent Lunesta, AstraZeneca's statin Crestor and Indevus' overactive bladder therapy Sanctura are among the new products to be included in UnitedHealth's postmarketing surveillance drug registry
Cymbalta “Mood” And “Pain” Claims May Include Fibromyalgia And Anxiety
Lilly is pursuing fibromyalgia and generalized anxiety disorder indications to add to the two currently approved indications for Cymbalta